FDA Approves Zoetis' Solensia To Control Osteoarthritis Pain In Cats

The FDA has approved Zoetis Inc's ZTS Solensia (frunevetmab injection) to control the pain of osteoarthritis (OA) in cats, helping improve their mobility, comfort, and overall well-being. 

• Solensia, prescribed as a once-monthly injection administered in the veterinary clinic, controls OA pain by targeting Nerve Growth Factor (NGF), a key driver in OA pain.
• The drug is the first and only injectable monoclonal antibody (mAb) treatment for feline OA pain approved in the U.S.
• After a single treatment, Solensia noticeably reduced OA pain. 77% of cat owners experienced seeing improvement in signs of pain after monthly treatment with Solensia in a 3-month study. 
• Also See: Zoetis Raises FY22 Dividend By 30%, Announces New Buyback Program Of $3.5B.
• In comparison, 67% of cat owners experienced an improvement in their cat's pain signs in the placebo group. 
• Solensia was found to be well-tolerated: the most common side effects were vomiting and injection site pain.
• Solensia is expected to be available to veterinarians in 2H of 2022. It is approved in the European Union and has been available to veterinarians since May 2021.
• Price Action: ZTS shares closed lower by 2.73% at $207.00 on Thursday.